Tasly Pharmaceutical Group Co Ltd (600535) — Cash Flow Reinvestment Rate
Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow Reinvestment Rate of 1.06x as of December 2025, reinvesting CN¥587.23 Million (capex CN¥117.78 Million plus investments CN¥-469.45 Million) from operating cash flow of CN¥552.13 Million. Check cash flow quality index of Tasly Pharmaceutical Group Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Tasly Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2001–2025)
Historical reinvestment intensity for Tasly Pharmaceutical Group Co Ltd across 24 annual periods. Explore Tasly Pharmaceutical Group Co Ltd (600535) investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year capital reinvestment analysis for Tasly Pharmaceutical Group Co Ltd. For live market cap and broader valuation context, see market cap of Tasly Pharmaceutical Group Co Ltd.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.52x | CN¥746.36 Million | CN¥1.42 Billion | CN¥381.26 Million | ▲ +31.0% |
| 2024 | 0.40x | CN¥805.29 Million | CN¥2.01 Billion | CN¥564.94 Million | ▼ -62.9% |
| 2023 | 1.08x | CN¥2.78 Billion | CN¥2.58 Billion | CN¥668.82 Million | ▲ +86.2% |
| 2022 | 0.58x | CN¥1.32 Billion | CN¥2.29 Billion | CN¥403.45 Million | ▲ +132.4% |
| 2021 | 0.25x | CN¥698.14 Million | CN¥2.80 Billion | CN¥571.73 Million | ▼ -0.4% |
| 2020 | 0.25x | CN¥448.14 Million | CN¥1.79 Billion | CN¥408.81 Million | ▼ -52.4% |
| 2019 | 0.53x | CN¥882.46 Million | CN¥1.68 Billion | CN¥730.78 Million | ▼ -5.5% |
| 2018 | 0.56x | CN¥830.62 Million | CN¥1.49 Billion | CN¥780.10 Million | ▼ -7.3% |
| 2016 | 0.60x | CN¥691.89 Million | CN¥1.15 Billion | CN¥524.68 Million | ▼ -81.7% |
| 2015 | 3.28x | CN¥1.12 Billion | CN¥340.00 Million | CN¥737.84 Million | ▲ +168.1% |
| 2014 | 1.22x | CN¥754.93 Million | CN¥616.76 Million | CN¥754.93 Million | ▼ -36.1% |
| 2013 | 1.92x | CN¥663.56 Million | CN¥346.17 Million | CN¥663.56 Million | ▲ +103.1% |
| 2012 | 0.94x | CN¥390.02 Million | CN¥413.31 Million | CN¥390.02 Million | ▼ -69.8% |
| 2011 | 3.13x | CN¥422.58 Million | CN¥135.14 Million | CN¥422.58 Million | ▲ +643.6% |
| 2010 | 0.42x | CN¥166.13 Million | CN¥395.05 Million | CN¥166.13 Million | ▲ +44.1% |
| 2009 | 0.29x | CN¥116.80 Million | CN¥400.39 Million | CN¥116.80 Million | ▼ -33.7% |
| 2008 | 0.44x | CN¥114.51 Million | CN¥260.21 Million | CN¥114.51 Million | ▼ -51.5% |
| 2007 | 0.91x | CN¥201.23 Million | CN¥221.55 Million | CN¥201.23 Million | ▼ -50.0% |
| 2006 | 1.82x | CN¥255.41 Million | CN¥140.56 Million | CN¥255.41 Million | ▲ +31.8% |
| 2005 | 1.38x | CN¥296.33 Million | CN¥214.90 Million | CN¥296.33 Million | ▼ -24.2% |
| 2004 | 1.82x | CN¥369.62 Million | CN¥203.27 Million | CN¥369.62 Million | ▼ -67.4% |
| 2003 | 5.57x | CN¥328.74 Million | CN¥59.00 Million | CN¥328.74 Million | ▲ +811.2% |
| 2002 | 0.61x | CN¥126.09 Million | CN¥206.22 Million | CN¥126.09 Million | ▼ -57.1% |
| 2001 | 1.42x | CN¥119.35 Million | CN¥83.77 Million | CN¥119.35 Million | — |